Invasive fungal infections in the pediatric population

References

• Dornbusch HJ, Manzoni P, Roilides E, Walsh TJ, Groll AH. Invasive fungal infections in children. Pediatr. Infect. Dis. J.28(8), 734–737 (2009).
   PubMed Web of Science ®Google Scholar
• Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J. Infect.33(1), 23–32 (1996).
   PubMed Web of Science ®Google Scholar
• Lehrnbecher T, Frank C, Engels K, Kriener S, Groll AH, Schwabe D. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J. Infect.61(3), 259–265 (2010).
   PubMed Web of Science ®Google Scholar
• Levy O, Martin S, Eichenwald E et al. Impaired innate immunity in the newborn: newborn neutrophils are deficient in bactericidal/permeability-increasing protein. Pediatrics104(6), 1327–1333 (1999).
   PubMed Web of Science ®Google Scholar
• Yossuck P, Nightengale BJ, Fortney JE, Gibson LF. Effect of morphine sulfate on neonatal neutrophil chemotaxis. Clin. J. Pain24(1), 76–82 (2008).
   PubMed Web of Science ®Google Scholar
• Lehrnbecher T, Foster C, Vazquez N, Mackall CL, Chanock SJ. Therapy-induced alterations in host defense in children receiving chemotherapy. J. Ped. Hematol. Oncol.19, 399–417 (1997).
   PubMed Web of Science ®Google Scholar
• Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin. Infect. Dis.41(9), 1232–1239 (2005).
   PubMed Web of Science ®Google Scholar
• Zaoutis T, Walsh TJ. Antifungal therapy for neonatal candidiasis. Curr. Opin. Infect. Dis.20(6), 592–597 (2007).
   PubMedGoogle Scholar
• Malani PN, Bradley SF, Little RS, Kauffman CA. Trends in species causing fungaemia in a tertiary care medical centre over 12 years. Mycoses44(11–12), 446–449 (2001).
   PubMed Web of Science ®Google Scholar
• Pappas PG, Rex JH, Lee J et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin. Infect. Dis.37(5), 634–643 (2003).
   PubMed Web of Science ®Google Scholar
• Burgos A, Zaoutis TE, Dvorak CC et al. Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics121(5), e1286–e1294 (2008).
   PubMed Web of Science ®Google Scholar
• Zaoutis TE, Heydon K, Chu JH, Walsh TJ, Steinbach WJ. Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics117(4), e711–e716 (2006).
   PubMed Web of Science ®Google Scholar
• Zaoutis TE, Roilides E, Chiou CC et al. Zygomycosis in children: a systematic review and analysis of reported cases. Pediatr. Infect. Dis. J.26(8), 723–727 (2007).
   PubMed Web of Science ®Google Scholar
• Roden MM, Zaoutis TE, Buchanan WL et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin. Infect. Dis.41(5), 634–653 (2005).
   PubMed Web of Science ®Google Scholar
• Bochennek K, Abolmaali N, Wittekindt B, Schwabe D, Klingebiel T, Lehrnbecher T. Diagnostic approaches for immunocompromised paediatric patients with pulmonary infiltrates. Clin. Microbiol. Infect.12(3), 199–201 (2006).
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Letscher-Bru V, Oprea C et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J. Clin. Oncol.20(7), 1898–1906 (2002).
   PubMed Web of Science ®Google Scholar
• Steinbach WJ, Addison RM, McLaughlin L et al. Prospective Aspergillus galactomannan antigen testing in pediatric hematopoietic stem cell transplant recipients. Pediatr. Infect. Dis. J.26(7), 558–564 (2007).
   PubMed Web of Science ®Google Scholar
• Smith PB, Benjamin DK Jr, Alexander BD, Johnson MD, Finkelman MA, Steinbach WJ. Quantification of 1,3-β-D-glucan levels in children: preliminary data for diagnostic use of the β-glucan assay in a pediatric setting. Clin. Vaccine Immunol.14(7), 924–925 (2007).
   PubMed Web of Science ®Google Scholar
• De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis.46, 1813–1821 (2008).
   PubMed Web of Science ®Google Scholar
• Caillot D, Couaillier JF, Bernard A et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J. Clin. Oncol.19(1), 253–259 (2001).
   PubMed Web of Science ®Google Scholar
• Allan BT, Patton D, Ramsey NK, Day DL. Pulmonary fungal infections after bone marrow transplantation. Pediatr. Radiol.18(2), 118–122 (1988).
   PubMed Web of Science ®Google Scholar
• Taccone A, Occhi M, Garaventa A, Manfredini L Viscoli C. CT of invasive pulmonary aspergillosis in children with cancer. Pediatr. Radiol.23(3), 177–180 (1993).
   PubMed Web of Science ®Google Scholar
• Thomas KE, Owens CM, Veys PA, Novelli V, Costoli V. The radiological spectrum of invasive aspergillosis in children: a 10-year review. Pediatr. Radiol.33(7), 453–460 (2003).
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Winston DJ et al. Posaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med.356(4), 348–359 (2007).
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Lipton JH, Vesole DH et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med.356(4), 335–347 (2007).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Adamson PC, Seibel NL et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob. Agents Chemother.49(11), 4536–4545 (2005).
   PubMed Web of Science ®Google Scholar
• Zaoutis TE, Jafri HS, Huang LM et al. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients. Pediatrics123(3), 877–884 (2009).
   PubMed Web of Science ®Google Scholar
• Maertens JA, Madero L, Reilly AF et al. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr. Infect. Dis. J.29(5), 415–420 (2010).
   PubMed Web of Science ®Google Scholar
• Seibel NL, Schwartz C, Arrieta A et al. Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob. Agents Chemother.49(8), 3317–3324 (2005).
   PubMed Web of Science ®Google Scholar
• Queiroz-Telles F, Berezin E, Leverger G et al. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr. Infect. Dis. J.27(9), 820–826 (2008).
   PubMed Web of Science ®Google Scholar
• van Burik JA, Ratanatharathorn V, Stepan DE et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin. Infect. Dis.39(10), 1407–1416 (2004).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Teppler H, Donowitz GR et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N. Engl. J. Med.351(14), 1391–1402 (2004).
   PubMed Web of Science ®Google Scholar
• Hope WW, Seibel NL, Schwartz CL et al. Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob. Agents Chemother.51(10), 3714–3719 (2007).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Karlsson MO, Driscoll T et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob. Agents Chemother.48(6), 2166–2172 (2004).
   PubMed Web of Science ®Google Scholar
• Karlsson MO, Lutsar I Milligan PA. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob. Agents Chemother.53(3), 935–944 (2009).
   PubMed Web of Science ®Google Scholar
• Neely M, Rushing T, Kovacs A, Jelliffe R Hoffman J. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin. Infect. Dis.50(1), 27–36 (2010).
   PubMed Web of Science ®Google Scholar